Pterostilbene improves glycaemic control in XXXX fed an obesogenic diet: involvement of skeletal muscle and liver.

@entity2308 @entity6 @entity67100 @entity19617 @entity35 @entity13343
UNASSIGNED: This study aims to determine whether pterostilbene improves glycaemic control in @entity35 showing insulin resistance induced by an obesogenic diet. @entity35 were divided into 3 groups: the control group and two groups treated with either 15 mg kg(-1) d(-1) (PT15) or 30 mg kg(-1) d(-1) of pterostilbene (PT30). HOMA-IR was decreased in both pterostilbene-treated groups, but this reduction was greater in the PT15 group (-45% and -22% respectively vs. the control group). The improvement of glycaemic control was not due to a delipidating effect of pterostilbene on skeletal muscle. In contrast, @entity19617 protein expression was increased (+58% and +52% vs. the control group), suggesting an improved glucose uptake. The phosphorylated- @entity2308 /total @entity2308 ratio was significantly enhanced in the PT30 group (+25%), and therefore a more efficient translocation of @entity19617 is likely. Additionally, in this group the amount of @entity67100 was significantly increased (+65%). These data suggest that the effect of pterostilbene on @entity2308 is mediated by this cytokine. In the liver, @entity13343 activity was significantly increased only in the PT15 group (+34%), and no changes were observed in glucose-6-phosphatase activity. The beneficial effect of pterostilbene on glycaemic control was more evident with the lower dose, probably because in the PT15 group both the muscle and the liver were contributing to this effect, but in the PT30 group only the skeletal muscle was responsible. In conclusion, pterostilbene improves glycaemic control in @entity35 showing insulin resistance induced by an obesogenic diet. An increase in hepatic @entity13343 activity, as well as in skeletal muscle glucose uptake, seems to be involved in the anti- @entity6 effect of this phenolic compound.
